Cancer Biology and Prevention in Diabetes

Cancer Biology and Prevention in Diabetes

The available evidence suggests a complex relationship between diabetes and cancer. Epidemiological data suggest a positive correlation, however, in certain types of cancer, a more complex picture emerges, such as in some site-specific cancers being specific to type I diabetes but not to type II dia...

Full description

Bibliographic Details
Main Authors:	Swayam Prakash Srivastava, Julie E. Goodwin
Format:	Article
Language:	English
Published:	MDPI AG 2020-06-01
Series:	Cells
Subjects:	metformin insulin thiazolidinediones incretins dipeptidyl peptidase 4 sodium-glucose cotransporter 2
Online Access:	https://www.mdpi.com/2073-4409/9/6/1380

Similar Items

Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin
by: Jong Ho Kim, et al.
Published: (2016-04-01)

Factors associated with the glucose‐lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials
by: Naoko Tajima, et al.
Published: (2020-05-01)

Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents
by: Atsushi Tanaka, et al.
Published: (2021-09-01)

Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease
by: Sook Jung Lee, et al.
Published: (2019-12-01)

Patients’ Preference Between DPP4i and SGLT2i for Type 2 Diabetes Treatment: A Cross-Sectional Evaluation
by: Costa Gil JE, et al.
Published: (2022-05-01)

Acute pancreatitis with gliptins: Is it a clinical reality?
by: Muthukrishnan Jayaraman, et al.
Published: (2013-01-01)

The multiple actions of dipeptidyl peptidase 4 (DPP-4) and its pharmacological inhibition on bone metabolism: a review
by: L. M. Pechmann, et al.
Published: (2024-07-01)

Which is better, high‐dose metformin monotherapy or low‐dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low‐dose metformin monotherapy? A randomized, cross‐over, continuous glucose monitoring‐based pilot study
by: Hiroshi Takahashi, et al.
Published: (2019-05-01)

A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus
by: Ira Gantz, et al.
Published: (2017-09-01)

Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale
by: Yassin SA, et al.
Published: (2017-03-01)

Sodium glucose cotransporter‐2 inhibitor was associated with an improvement in left ventricular systolic function in patients with type 2 diabetes mellitus with impaired left ventricular systolic function
by: Yi‐Hsin Chan, et al.
Published: (2020-10-01)

Choosing a Gliptin
by: Vishal Gupta, et al.
Published: (2011-01-01)

Effects of metformin and alogliptin on body composition in people with type 2 diabetes
by: Yumie Takeshita, et al.
Published: (2019-05-01)

Incident cancer risk in dipeptidyl peptidase-4 inhibitor-treated patients with type 2 diabetes mellitus
by: Choi YJ, et al.
Published: (2019-08-01)

The impact of innovative glucose-lowering drugs on the course and outcome of COVID-19 in patients with type 2 diabetes mellitus
by: T. N. Markova, et al.
Published: (2024-05-01)

Angioprotektivnoe properties lowering drugs from the group of inhibitors of dipeptidyl peptidase-4
by: E V Oskola, et al.
Published: (2013-09-01)

The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
by: Ann Wan-Chin Ling, et al.
Published: (2020-11-01)

Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach
by: Awadhesh Kumar Singh
Published: (2014-01-01)

New Drugs for Type 2 Diabetes: New Hopes and New Concerns About the Skeleton
by: Zehra Berberoglu
Published: (2016-10-01)

Adjunctive therapy for glucose control in patients with type 1 diabetes
by: Harris K, et al.
Published: (2018-04-01)

Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
by: Kushner P
Published: (2010-04-01)

Las incretinas como nueva opción terapéutica en la diabetes mellitus tipo 2
by: Félix Andrés Reyes Sanamé, et al.

Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential
by: Nasser Mikhail
Published: (2008-12-01)

Initial combination therapy for patients with type 2 diabetes mellitus: considerations for metformin plus linagliptin
by: Jeffrey Freeman
Published: (2013-08-01)

Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study
by: Nam Hoon Kim, et al.
Published: (2017-06-01)

A review on phytochemical and pharmacological facets of tropical ethnomedicinal plants as reformed DPP-IV inhibitors to regulate incretin activity
by: Srishti Chhabria, et al.
Published: (2022-11-01)

Editorial: Diabetic kidney disease: routes to drug development, pharmacology and underlying molecular mechanisms
by: Divya Bhatia, et al.
Published: (2023-08-01)

Dipeptidyl peptidase 4 inhibitor improves insulin resistance in Japanese patients with type 2 diabetes: a single-arm study, a brief report
by: Tsuyoshi Okura, et al.
Published: (2022-06-01)

Effects of 6-Month Sitagliptin Treatment on Insulin and Glucagon Responses in Korean Patients with Type 2 Diabetes Mellitus
by: Hae Kyung Yang, et al.
Published: (2015-08-01)

Effects of Sodium-Glucose Cotransporter-2 Inhibitors and Thiazolidinedione on New-Onset Atrial Fibrillation Risk to Patients with Type 2 Diabetes
by: Haegeun Song, et al.
Published: (2022-09-01)

Pathogenetic substantiation and effectiveness of vildagliptin use inpatients with diabetes mellitus type 2
Published: (2009-09-01)

Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of ActionOral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action
by: Graziella Bruno, et al.
Published: (2010-09-01)

The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study
by: Arwa Younis, et al.
Published: (2017-05-01)

The optimal second-line therapy for older adults with type 2 diabetes mellitus: protocol for a systematic review and network meta-analysis using individual participant data (IPD)
by: Jingya Wang, et al.
Published: (2024-06-01)

Comparative effects of incretin-based therapy on doxorubicin-induced nephrotoxicity in rats: the role of SIRT1/Nrf2/NF-κB/TNF-α signaling pathways
by: Sandy R. Botros, et al.
Published: (2024-02-01)

Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes
by: Anand-Krishna Singh, et al.
Published: (2021-06-01)

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus
by: Karyekar CS, et al.
Published: (2013-04-01)

Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION)
by: Byung Wan Lee, et al.
Published: (2023-06-01)

Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
by: Carolyn F. Deacon
Published: (2019-02-01)

Corrigendum: Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
by: Carolyn F. Deacon
Published: (2019-05-01)